Results 161 to 170 of about 2,438,119 (300)

The Value of Using Bedside Point of Care Testing for International Normalized Ratio in Patients on Warfarin Undergoing Dental Procedures and Bleeding Assessment; A Single Center Prospective Study

open access: yesJournal of Blood Medicine
Abdullah Albarkheel,1 Hawazen Alshareef,1 Amal Albar,1 Sohayla Youssef Altbaili,1 Mohammed Ali Alminaqash,1 Amjad Alotibie,2 Aamir Sheikh,3,4 Abdullah Alahmadi,3 Badar Alaifan,3 Hani Tamim,4 Tarek Owaidah2,4 1Dental Department, King Faisal Specialist ...
Albarkheel A   +10 more
doaj  

Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in Australia. [PDF]

open access: yesJ Viral Hepat
Conway A   +7 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

A Molecularly Imprinted Membrane for High-Density Lipoprotein Extraction in Point-of-Care Testing. [PDF]

open access: yesBiosensors (Basel)
de Gregorio GL   +7 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy